FDA approves Axonics’ neurostimulator
pharmafile | February 1, 2023 | News story | Medical Communications |
US-based medtech company Axonics have received FDA approval for their fourth-generation, rechargeable sacral neuromodulation system for the treatment of chronic incontinence.
Axonics R20 is an implantable device which lasts for 20 years and only needs charging every six to ten months for one hour ‒ its third-generation R15 needed charging once a month for one hour. This improvement was made so patients could have an improved quality of life without concerns over the device’s battery life.
The devices use Axonic’s sacral neuromodulation (SNM) system, which provides patients with overactive bladder or faecal incontinence with a long-term, easy-to-use and safe therapy. Both use the same small 5cc form factor and pair to the same tined lead and intuitive patient remote control.
Axonics executive vice president and chief marketing and strategy officer John Woock said: “Patients with overactive bladder tell us that first and foremost, they value efficacy and a long-lived solution to address their chronic condition. The Axonics R20, which requires recharging just twice per year, represents another significant breakthrough for rechargeable neuromodulation devices and underscores our commitment to continuous innovation. We are confident that Axonics’ keen focus on the incontinence patient population and increasing public awareness of sacral neuromodulation has the potential to drive significant market expansion in the years ahead.”